false000150327400015032742026-11-182026-11-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________________________
FORM 8-K
______________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 18, 2026
_________________________________________________
QUANTERIX CORPORATION
(Exact name of registrant as specified in its charter)
_________________________________________________
Delaware001-3831920-8957988
(State or other jurisdiction
of incorporation)
(Commission File Number)(IRS Employer
Identification No.)
900 Middlesex Turnpike
Billerica, MA
01821
(Address of principal executive offices)
(Zip Code)
(617) 301-9400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading symbol(s):
Name of each exchange on which
registered:
Common Stock, $0.001 par value per shareQTRXThe Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 18, 2026, Quanterix Corporation (the “Company”) announced that Everett Cunningham has resigned as President and Chief Executive Officer of the Company and as a member of the Company’s Board of Directors (the “Board”), both effective as of November 18, 2026. Mr. Cunningham has accepted another opportunity, and his departure is not related to any disagreements with the Company on any matter relating to its operations, policies, practices (financial or otherwise) or any issues regarding financial disclosures, accounting, or legal matters. Mr. Cunningham will remain available to assist with an orderly transition of his responsibilities through December 11, 2026.
Pending the Board’s search for a permanent President and Chief Executive Officer, the Company has appointed James Gute, currently serving as the Company’s Chief Commercial Officer, to serve as the Company’s Interim President and Chief Executive Officer, effective November 18, 2026. Mr. Gute, age 52, joined the Company in August 2026 as Chief Commercial Officer. Prior to joining the Company, Mr. Gute served as Senior Vice President and Commercial Manager, General Screening at Exact Sciences (now Abbott Laboratories, Cancer Diagnostics) from August 2024 to August 2026, and as General Manager, Western Region at the same organization from January 2022 to August 2024. Prior to that, he held several roles at GE Healthcare over a period of 18 years, most recently serving as President of the North Central Region.
Mr. Gute and his immediate family members are not party to any related party transactions for which disclosure would be required pursuant to Item 404(a) of Regulation S-K. There is no family relationship between Mr. Gute and any of the Company’s directors or executive officers and no arrangements or understandings with other persons pursuant to which Mr. Gute was selected as an officer.
In connection with his appointment as Interim President and Chief Executive Officer, Mr. Gute will be paid a salary of $750,000 on an annualized basis while fulfilling the role.
Item 7.01    Regulation FD Disclosure.
On November 18, 2026, the Company issued a press release to announce Mr. Cunningham’s resignation and the appointment of Mr. Gute (the “Release”). A copy of the Release is attached as Exhibit 99.1 and incorporated herein by reference.
The information contained or incorporated in this Item 7.01, including Exhibit 99.1, is being furnished, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01    Financial Statements and Exhibits.
(d)Exhibits
Exhibit
No.
Description
99.1
104Cover Page Interactive Data File (embedded within the inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
QUANTERIX CORPORATION
By:/s/ Jason Faessler
Jason Faessler
Chief Financial Officer
Date: November 18, 2026



ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-99.1

XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

IDEA: R1.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: qtrx-20261118_htm.xml